Jakarta, November 13, 2025 – PT Etana Biotechnologies Indonesia (Etana), together with CanSino Biologics Inc., has officially initiated the Phase I Clinical Trial of an inhaled Tuberculosis (TB) vaccine in Indonesia. This inhaled TB booster vaccine is a recombinant human adenovirus type 5–based vaccine and represents an innovative global TB booster designed for individuals who have previously received the Bacillus Calmette-Guérin (BCG) vaccine.
Read MoreYogyakarta, October 6, 2025 — PT Etana Biotechnologies Indonesia together with the Faculty of Pharmacy, Universitas Gadjah Mada (UGM) held the Indonesia Biopharmaceutical Summit (IBS) 2025, a strategic forum bringing together stakeholders from academia, industry, and government sectors. Carrying the theme “Shaping the Future of Biopharma in Indonesia”, this event serves as an important momentum to drive innovation and strengthen the biotechnology ecosystem toward national health sovereignty in Indonesia.
Read MoreJakarta, October 21, 2025 – PT Etana Biotechnologies Indonesia (Etana) reinforce its commitment to delivering high-quality, innovative, and halalcompliant ealth products. This commitment is realized through obtaining the halal certificate for its Enoxaparin Sodium product from the Assessment Institute for Foods, Drugs, and Cosmetics of the Indonesian Ulema Council (LPPOM MUI).
Read MoreJakarta, 30 September 2025 - PT Etana Biotechnologies Indonesia (Etana) has officially signed a strategic partnership with DEG Impulse, a subsidiary of DEG - Deutsche Investitions- und Entwicklungsgesellschaft mbH, to implement a digital transformation of the company’s core quality management system.
Read MoreJakarta, August 28, 2025 – PT Etana Biotechnologies Indonesia (Etana) has officially been designated as one of the Centers of Excellence for Vaccine and Biotechnology Development by the Ministry of Health of the Republic of Indonesia. The designation is stated in the Decree of the Director General of Pharmaceuticals and Medical Devices No. HK.02.02/E/1504/2025.
Read MoreJakarta, July 14, 2025 – PT Etana Biotechnologies Indonesia (Etana), a national biopharmaceutical company focused on developing treatments for metabolic and chronic diseases, has signed a collaboration agreement with Universitas Indonesia Hospital (RSUI) to conduct clinical research on therapy for Type 2 Diabetes Mellitus.
Read More
